Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans-Reference-Cited by-同舟云学术

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Published:2015-02-12 Issue:7 Volume:125 Page:1180-1188
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Hofbauer Christoph J.¹,Whelan Shawn F. J.¹,Hirschler Maria¹,Allacher Peter¹,Horling Frank M.¹,Lawo John-Philip¹,Oldenburg Johannes²,Tiede Andreas³,Male Christoph⁴,Windyga Jerzy⁵,Greinacher Andreas⁶,Knöbl Paul N.⁷,Schrenk Gerald¹,Koehn Jadranka¹,Scheiflinger Friedrich¹,Reipert Birgit M.¹

Affiliation:

1. Baxter BioScience, Vienna, Austria;

2. Institute for Experimental Hematology and Transfusion Medicine, Bonn, Germany;

3. Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;

4. Department of Pediatrics, Medical University of Vienna, Vienna, Austria;

5. Institute of Hematology and Transfusion Medicine, Warsaw, Poland;

6. Institute for Immunology and Transfusion Medicine, Greifswald Medical School, Greifswald, Germany; and

7. Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

Abstract

Key Points A new technology is presented to assess apparent affinities of FVIII-specific antibodies, differentiated for isotypes and IgG subclasses. Affinities of FVIII-specific antibodies in patients with FVIII inhibitors are up to 100-fold higher than in patients without inhibitors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/7/1180/1389064/1180.pdf

Reference30 articles.

1. Factor VIII inhibitors: a 50-year perspective.;Green;Haemophilia,2011

2. Acquired factor VIII inhibitors [published correction appears in Blood. 2009;113(21):5368].;Franchini;Blood,2008

3. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.;Whelan;Blood,2013

4. Germinal center selection and the development of memory B and plasma cells.;Shlomchik;Immunol Rev,2012

5. Plasma cell development and survival.;Oracki;Immunol Rev,2010

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hémophilie acquise : quoi de neuf en 2024 ?;La Revue de Médecine Interne;2024-09

2. Acid Treatment of FVIII-Containing Plasma Samples Unmasks a Broad Spectrum of FVIII-Specific Antibodies in ELISA;Hämostaseologie;2024-07-15

3. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A;Molecular Therapy;2024-07

4. Comprehensive domain-specific analysis and immunoglobulin G profiling of anti–factor VIII antibodies using a bead-based multiplex immunoassay;Journal of Thrombosis and Haemostasis;2024-06

5. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A;Blood Advances;2024-05-30